New Hampshire will receive nearly $30 million as part of a $7.4 billion settlement with Purdue Pharma and the Sackler family that has become legally effective.
The settlement resolves litigation against Purdue and the Sacklers over their role in producing and aggressively marketing opioids in the U.S., according to a May 5 news release from the office of New Hampshire’s attorney general. Fifty-five attorneys general, including all eligible U.S. states and territories, signed onto the agreement.
New Hampshire is expected to receive $29,549,827.85 over the next 10 years, including $16,252,405.32 in the first three years. That amount includes $7,387,456.96 in the first year, $4,727,972.46 in the second and $4,136,975.90 in the third.
The settlement also permanently bars the Sackler family from selling opioids in the U.S. and transfers Purdue’s manufacturing operations effective May 5 to Knao Pharma, which “will be overseen by a board with no connection to Purdue,” the release said. The agreement also provides for the release of more than 30 million documents related to Purdue’s opioid business.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
